These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1970776)

  • 1. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
    Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
    Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
    Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
    Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.
    Karim A; Kook C; Novotney RL; Zagarella J; Campion J
    Drug Metab Dispos; 1978; 6(3):338-45. PubMed ID: 26556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.
    Cook CS; Karim A; Sollman P
    Drug Metab Dispos; 1982; 10(2):116-21. PubMed ID: 6124395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
    le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
    Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography.
    Takahashi H; Tamura A; Ogata H; Masuhara K
    J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
    Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of a disopyramide metabolite in renal failure.
    Inagaki Y; Amano I; Otsu T
    ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human pharmacokinetics and metabolism of disopyramide enantiomers.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
    Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
    Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Accumulation of a disopyramide metabolite in renal failure].
    Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
    Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interspecies differences in enantioselective mono-N-dealkylation of disopyramide by human and mouse liver microsomes.
    Echizen H; Mochizuki K; Tani M; Ishizaki T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1518-25. PubMed ID: 8138963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of disopyramide and its mono-N-dealkylated metabolite in conscious dogs with chronic atrioventricular block: plasma concentration-response relationships.
    Dubray C; Boucher M; Paire M; Pinatel H; Duchêne-Marullaz P
    J Cardiovasc Pharmacol; 1986; 8(6):1229-34. PubMed ID: 2434751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes.
    Echizen H; Kawasaki H; Chiba K; Tani M; Ishizaki T
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1425-31. PubMed ID: 8450476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
    Aso R; Ohashi K; Katoh T; Ogata H
    Int J Clin Pharmacol Res; 2001; 21(3-4):137-46. PubMed ID: 12067143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data.
    Le Corre P; Ratanasavanh D; Chevanne F; Gibassier D; Sado P; Le Verge R; Guillouzo A
    Chirality; 1991; 3(5):405-11. PubMed ID: 1756095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency and voltage-dependent effects of mono-N-dealkyldisopyramide, the major metabolite of disopyramide, in canine ventricular tissue.
    Toy W; Sasyniuk BI
    J Pharmacol Exp Ther; 1990 Aug; 254(2):603-11. PubMed ID: 2166798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Pike E; Lunde PK
    Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.